Member Info for bewise

Buddy, click on presentation section and you will see it.

Buddy, look under events and presentations heading then click presentations and you will see it.

New presentation on the vrp website..check it out guys!

The next results are due soon and imo will be another positive but what next? We find ourselves in the midst of something extraordinary and unprecedented in our generation, the world is going into lockdown and companies are crashing. For us the cv disease attacks the respiratory system and the vrp compound aids the respiratory system for people who are most at risk. Will our compound aid the recovery of people with cv and underlying health conditions such as copd and asthma, who knows! i would really hope it does. On the release of the next test results i think i would also appreciate as a investor a reassuring update to calm market nerves...

Good interview by vrp medical director today on proactive..

Thanks Rhodi, yes the waiting game has taken years lol, will there be gold at the end of the rainbow? I really do hope so! The compound could have the potential imo re Corona virus to treat symptoms. I cannot remember in my lifetime whole cities with millions of people being shut down!!

The new appointments will create a new dynamic within the company as we are seeing. They bring a wealth of experience to Verona from the US and I believe the marketing / negotiations strategy will change dramatically in relation to the compound. After the next set of results if good I believe will set us up for a deal/ licencing/ partnership....its a waiting game...

It will continue to rise in anticipation of the next set of results this quarter then FDA
meeting....interesting times ahead and hopefully that long awaited shareholder value will materialize...i can but dream.

Imo the sp is not responding as there is uncertainty over funding for P3, its as simple as that. The compound obviously works but funding is the question...hoping for partnership/out licensing deal ....

Good result with publication

As i have said If we can get a good set of results on the next rns my expectation of a partnership or licencing deal rises considerably...all to play for...hopefully the 3 new appointments will deliver what all of us are waiting for...

Positive vote for the new team and anticipation of the next set of results and if positive sets us up quite nicely for a deal / funding for P3!

That's only your opinion which off course you are entitled to but you are making a speculative statement with no knowledge of the actual truth so for the time being i am taking the RNS at face value as I have no reason to at this point to think anything else. The news for me is a positive as i believe imo the ex ceo took the compound development as far as he could. At the end of the day the sp will rise or fall on funding/partnership news, this sp is dismal and hard to watch..

As i have no 3rd sense in these matters I can just take it at face value that the guy just wanted to retire at a still young enough age in his 60's which i would imagine is the aspiration for most of us who are still working...

At the end of the day the ceo is retiring, I dont see it as being a big deal nor a statement on the company. I would imagine/asume the Board knew his intentions for a while due to the fact they have quickly appointed a replacement. All eyes are now on the next set of results, FDA and funding for P3... i do think a fresh pair of hands here is definitely a good thing to push things forward...

The change of C.E.O. imo is a good development along with the finance guy as we enter a new phase, maybe now with fresh hands in place we can see the start of some decent momentum which imo has been lacking...

Could ensifentrine help to alleviate the side effects of sufferers re the coronavirus if this becomes a pandemic??? Any thoughts?

Being walked down on nasdaq. The results in the RNS are outstanding but without funding certainty for P3 this share will not go to fair value. Partnership news would be transformational but till (if) then the market will hate uncertainty.

If vrp anticipate commencing P3 in Q3 or Q4 they must have a solution to funding in mind at this point, all to be revealed later this year i would imagine after FDA approval... partnership would be best for the company and the investors not to mention the sp...I'm hoping for a miracle this year lol

The biggest question for 2020 is the funding of P3. Imo Verona defo need a partnership to push ensifentrine through. I optimistically believe the results today will catch the attention of large bio's. Its has been a very long journey with vrp and I hope to see significant shareholder value but I also know this is a extremely high risk investment. What will 2020 bring us!